MedTrace Logo

Melatonin and Radiation Therapy in Treating Patients With Brain Metastases

NCT00031967 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-10-22

No results posted yet for this study

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as melatonin may make tumor cells more sensitive to radiation therapy and may protect normal cells from the side effects of radiation therapy.

PURPOSE: Randomized phase II trial to determine the effectiveness of combining melatonin with radiation therapy in treating patients who have brain metastases.

Conditions

  • Metastatic Cancer
  • Radiation Toxicity
  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

therapeutic melatonin

RADIATION

radiation therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Radiation Therapy Oncology Group

    lead NETWORK

Principal Investigators

  • Lawrence B. Berk, MD, PhD · Newark Radiation Oncology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
0 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-05-31
Primary Completion
2004-03-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00031967 on ClinicalTrials.gov